ARNAY was established by Sudhir Agrawal, who, over the last three decades, has been active in research in this field, both in academia and industry.
ARNAY was established by Sudhir Agrawal, who, over the last three decades, has been active in research in this field, both in academia and industry.
Recently, a new class of drugs composed of short RNA and DNA has been approved. These drugs, called antisense and siRNA, bind to disease-associated aberrant RNA in the body and modulate the translation of disease-associated proteins. Based on the genetic sequence of a specific RNA, a complementary short RNA and DNA can be created to hybridize to the targeted RNA.
While this seems simple, lessons have been learned over four decades on providing drug-like properties to these short pieces of RNA and DNA. The important factors of success lie in the nucleotide sequence and the chemistry used to imbue the sequence with drug-like properties. While the antisense sequence is complementary to the RNA, challenges arise when the sequence also acts as a pathogen-associated molecular pattern and triggers unintended immune responses. Chemical Engineering of DNA and RNA has been shown to modulate immune responses.
Once an appropriate sequence is selected, the chemistry that provides the selected RNA drug-like properties must be applied. For example, gapmer chemistry, which I developed in the early 90s, is now widely used in antisense drug candidates that have been approved.
ARNAY continues fine-tuning sequences and engineering novel chemistry to create potent and safe drugs. With three decades of insight, ARNAY has designed novel chemical structures that significantly increase the potency and specificity of RNA therapeutic candidates. These chemical structures have broad applicability in developing RNA therapeutics and immunotherapy.
Once an appropriate sequence is selected, the chemistry that provides the selected RNA drug-like properties must be applied. For example, gapmer chemistry, which I developed in the early 90s, is now widely used in antisense drug candidates that have been approved.
ARNAY continues fine-tuning sequences and engineering novel chemistry to create potent and safe drugs. With three decades of insight, ARNAY has designed novel chemical structures that significantly increase the potency and specificity of RNA therapeutic candidates. These chemical structures have broad applicability in developing RNA therapeutics and immunotherapy. ARNAY has entered into a collaboration and licensing agreement with Alloy Therapeutics to advance this platform further and to be used by researchers and entrepreneurs to create RNA therapeutics.
Explore our collection of related articles and resources that validate the groundbreaking work we do in the field of RNA therapeutics. Our commitment to scientific excellence is evident in the research and discoveries we’ve made over the years.
Contact Sudhir Agrawal, the visionary behind ARNAY Sciences. Whether you’re an established researcher, entrepreneur, or simply curious about the potential of RNA engineering, Sudhir and our team are here to assist you in realizing your goals and advancing the field of life sciences.
Explore our collection of related articles and resources that validate the groundbreaking work we do in the field of RNA therapeutics. Our commitment to scientific excellence is evident in the research and discoveries we’ve made over the years.
Copyright © 2024. All rights reserved
